23andMe
program first clinical stage oncology antibody targeting low head of therapeutics development | 23andMe
Company
Deck Type
Sector
Industry
Deck date
January 2022
Slide
43 of 78
Similar slides by 23andMe
See diffirences between slides (animation)
Investor Day
January 2022
using genetics to inform clinical development low head of therapeutics development | 23andMe
Investor Day
January 2022
me a novel oncology antibody targeting low head of therapeutics development and senior clinical development fellow me | 23andMe
Related slides by other companies
AbCellera
Results
February 2023
i a a partnered programs technology development efforts with potential to generate first in class wholly owned assets | AbCellera
AbCellera
Results
May 2023
all programs leverage partnerships partner initiated programs technology development discovery programs development programs partnered programs i yee | AbCellera
Aeva
Results
March 2023
objectives | Aeva
Other recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
January 2024
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io